Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Интернет]. 31. Децембар 2025. [цитирано 14. Април 2026.];40(2):251-62. Available at: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001